Literature DB >> 22972833

Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains.

Luke T Daum1, John D Rodriguez, Sue A Worthy, Nazir A Ismail, Shaheed V Omar, Andries W Dreyer, P Bernard Fourie, Anwar A Hoosen, James P Chambers, Gerald W Fischer.   

Abstract

A novel protocol for full-length Mycobacterium tuberculosis gene analysis of first- and second-line drug resistance was developed using the Ion Torrent Personal Genome Machine (PGM). Five genes-rpoB (rifampin), katG (isoniazid), pncA (pyrazinamide), gyrA (ofloxacin/fluoroquinolone), and rrs (aminoglycosides)-were amplified and sequenced, and results were compared to those obtained by genotypic Hain line probe assay (LPA) and phenotypic Bactec MGIT 960 analysis using 26 geographically diverse South African clinical isolates collected between July and November 2011. Ion Torrent sequencing exhibited 100% (26/26) concordance to phenotypic resistance obtained by MGIT 960 culture and genotypic rpoB and katG results by LPA. In several rifampin-resistant isolates, Ion Torrent sequencing revealed uncommon substitutions (H526R and D516G) that did not have a defined mutation by LPA. Importantly, previously uncharacterized mutations in rpoB (V194I), rrs (G878A), and pncA (Q122Stop) genes were observed. Ion Torrent sequencing may facilitate tracking and monitoring geographically diverse multidrug-resistant and extensively drug-resistant strains and could potentially be integrated into selected regional and reference settings throughout Africa, India, and China.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22972833      PMCID: PMC3502959          DOI: 10.1128/JCM.01893-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination.

Authors:  S Sreevatsan; X Pan; K E Stockbauer; N D Connell; B N Kreiswirth; T S Whittam; J M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Molecular analysis of isoniazid resistance in Mycobacterium tuberculosis isolates recovered from South Korea.

Authors:  Soo-Young Kim; Yeon-Joon Park; Won-Il Kim; Sun-Hwa Lee; Chulhun Ludgerus Chang; Seok-Jin Kang; Chang-Suk Kang
Journal:  Diagn Microbiol Infect Dis       Date:  2003-11       Impact factor: 2.803

3.  A clinical specimen collection and transport medium for molecular diagnostic and genomic applications.

Authors:  L T Daum; S A Worthy; K C Yim; M Nogueras; R F Schuman; Y W Choi; G W Fischer
Journal:  Epidemiol Infect       Date:  2010-12-16       Impact factor: 2.451

4.  Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates.

Authors:  Doris Hillemann; Michael Weizenegger; Tanja Kubica; Elvira Richter; Stefan Niemann
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene.

Authors:  Y Suzuki; C Katsukawa; A Tamaru; C Abe; M Makino; Y Mizuguchi; H Taniguchi
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

6.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

Authors:  A Telenti; P Imboden; F Marchesi; D Lowrie; S Cole; M J Colston; L Matter; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

7.  Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance.

Authors:  D A Rouse; J A DeVito; Z Li; H Byer; S L Morris
Journal:  Mol Microbiol       Date:  1996-11       Impact factor: 3.501

8.  Characterization of rifampin-resistance in pathogenic mycobacteria.

Authors:  D L Williams; C Waguespack; K Eisenach; J T Crawford; F Portaels; M Salfinger; C M Nolan; C Abe; V Sticht-Groh; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Authors:  Alexandra Aubry; Xiao-Su Pan; L Mark Fisher; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa.

Authors:  Thomas R Ioerger; Sunwoo Koo; Eun-Gyu No; Xiaohua Chen; Michelle H Larsen; William R Jacobs; Manormoney Pillay; A Willem Sturm; James C Sacchettini
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more
  32 in total

1.  Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a Molecular Analysis of Historical Isolates.

Authors:  Nontuthuko E Maningi; Luke T Daum; John D Rodriguez; Halima M Said; Remco P H Peters; John Osei Sekyere; Gerald W Fischer; James P Chambers; P Bernard Fourie
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

Review 2.  Whole-genome sequencing in outbreak analysis.

Authors:  Carol A Gilchrist; Stephen D Turner; Margaret F Riley; William A Petri; Erik L Hewlett
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 3.  Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations.

Authors:  Jesse J Salk; Michael W Schmitt; Lawrence A Loeb
Journal:  Nat Rev Genet       Date:  2018-03-26       Impact factor: 53.242

4.  Improved Detection by Next-Generation Sequencing of Pyrazinamide Resistance in Mycobacterium tuberculosis Isolates.

Authors:  Nontuthuko E Maningi; Luke T Daum; John D Rodriguez; Matsie Mphahlele; Remco P H Peters; Gerald W Fischer; James P Chambers; P Bernard Fourie
Journal:  J Clin Microbiol       Date:  2015-09-16       Impact factor: 5.948

Review 5.  Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates.

Authors:  Sarah M Ramirez-Busby; Faramarz Valafar
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

6.  Next-Generation Sequencing for Characterizing Drug Resistance-Conferring Mycobacterium tuberculosis Genes from Clinical Isolates in the Ukraine.

Authors:  L T Daum; O S Konstantynovska; O S Solodiankin; O O Liashenko; P I Poteiko; V I Bolotin; I I Hrek; A V Rohozhyn; J D Rodriguez; G W Fischer; J P Chambers; A P Gerilovych
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

Review 7.  Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Authors:  William A Wells; Catharina C Boehme; Frank G J Cobelens; Colleen Daniels; David Dowdy; Elizabeth Gardiner; Jan Gheuens; Peter Kim; Michael E Kimerling; Barry Kreiswirth; Christian Lienhardt; Khisi Mdluli; Madhukar Pai; Mark D Perkins; Trevor Peter; Matteo Zignol; Alimuddin Zumla; Marco Schito
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

8.  Tuberculosis-spoligo-rifampin-isoniazid typing: an all-in-one assay technique for surveillance and control of multidrug-resistant tuberculosis on Luminex devices.

Authors:  Michel Kiréopori Gomgnimbou; Iván Hernández-Neuta; Stefan Panaiotov; Elizabeta Bachiyska; Juan Carlos Palomino; Anandi Martin; Patricia del Portillo; Guislaine Refregier; Christophe Sola
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

9.  Ion Torrent sequencing for conducting genome-wide scans for mutation mapping analysis.

Authors:  Rama Rao Damerla; Bishwanath Chatterjee; You Li; Richard J B Francis; Sarosh N Fatakia; Cecilia W Lo
Journal:  Mamm Genome       Date:  2013-12-05       Impact factor: 2.957

10.  Identification of Mycobacterium species and Mycobacterium tuberculosis complex resistance determinants by use of PCR-electrospray ionization mass spectrometry.

Authors:  Patricia J Simner; Seanne P Buckwalter; James R Uhl; Nancy L Wengenack
Journal:  J Clin Microbiol       Date:  2013-08-14       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.